Filing Flows › Health Care › Usana Health Sciences (USNA)
Usana Health Sciences (USNA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Usana Health Sciences (USNA) Q2 2026 earnings results →
Q2 2026 Revenue down 5% year over year to $223M · 13¢ of every $1 of revenue lost · operating margin -9.0%
Usana Health Sciences made $223M in Q2 2026 (-5% Y/Y). Operating margin -9.0%, net loss $28.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $223.3M in Q2 2026, down 5% year over year and down 11% from the previous quarter.
Gross margin was 78.3%, down 0.4 points from Q2 2025. Operating costs exceeded revenue by $20.0M, an operating margin of -9.0%. Operating expenses grew 15% against a revenue fall of 5%. The fastest-growing cost line was Other operating costs (+29%). The quarter ended with a net loss of $28.0M, after a profit of $7.0M the previous quarter. Minority interests bore $6.6M of it: to shareholders the quarter was a loss of $21.4M.
Operating cash flow was $23.3M (up 91% year over year). Non-cash charges added back $7.7M of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items added $40.2M. Capital expenditures of $3.2M left free cash flow of $20.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $223M | -5% | -9.0% | −$28.0M | $23.3M |
| Q1 2026 | 10-Q | May 12, 2026 | $250M | +0.3% | 5.5% | $7.5M | $9.8M |
| Q4 2025 | 10-K | Mar 16, 2026 | $226M | +6% | 1.7% | −$1.6M | −$3.4M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $214M | +7% | 0.6% | −$6.7M | −$2.0M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $236M | +11% | 7.1% | $9.7M | $12.2M |
| Q1 2025 | 10-Q | May 6, 2025 | $250M | +10% | 6.3% | $9.3M | $15.5M |
| Q4 2024 | 10-K | Mar 12, 2025 | $214M | -3% | 3.8% | $4.5M | $5.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Usana Health Sciences
USANA Health Sciences, Inc. develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold throughout the world. In 2025, we generated $925 million in net sales and finished the year with approximately 387,000 active Customers in our core nutritional business. We were founded in 1992 by Myron W. Wentz, Ph.D. and since that time, we have developed and manufactured high quality, science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness. We are committed to continuous product innovation and sound scientific research. We have operations in 25 geographic markets worldwide.
In its own words, from its 10-K, filed Mar 16, 2026.
Usana Health Sciences against its Medicinal Chemicals & Botanical Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -5% against the peers' median +7%. Operating margin: -9.0% against the peers' median 4.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| USNA Usana Health Sciences | Q2 2026 | $223M | -5% | -9.0% |
| CURLF Curaleaf Holdings | Q3 2026 | $353M | +11% | 0.8% |
| TLRY Tilray Brands | Q1 FY27 | $257M | +23% | -9.4% |
| TRLV Trulieve Cannabis | Q3 2026 | $230M | -20% | 18.5% |
| AAWH Ascend Wellness Holdings | Q2 2026 | $126M | -0.9% | 4.2% |
| CRON Cronos Group | Q3 2026 | $83.9M | +72% | 10.8% |
| CGC Canopy Growth | Q2 FY27 | $71.1M | +20% | -23.1% |
| JUSH Jushi Holdings | Q3 2026 | $70.5M | +7% | 5.0% |
| BTMD biote | Q3 2026 | $43.3M | -10% | 5.7% |
Source: Usana Health Sciences 10-Q on SEC EDGAR · CIK 896264 · Medicinal Chemicals & Botanical Products
13F: who owns USNA and who is buying
More on USNA
- How Usana Health Sciences makes money: revenue by segment
- Usana Health Sciences next earnings date and what analysts expect
- Usana Health Sciences stock forecast, price target and fair value
- Who owns Usana Health Sciences stock: holders, funds and Congress trades
- Usana Health Sciences guidance and outlook
- Is Usana Health Sciences a takeover target? LBO and rumors
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results